Sökning: WFRF:(Buyse M A) >
Overall survival be...
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial
-
- Oakman, C (författare)
- Hospital Prato, Italy
-
- Francis, P A. (författare)
- Peter MacCallum Cancer Centre, Australia
-
- Crown, J (författare)
- Irish Clin Oncology Research Grp, Ireland
-
visa fler...
-
- Quinaux, E (författare)
- Int Institute Drug Dev, Belgium
-
- Buyse, M (författare)
- Int Institute Drug Dev, Belgium
-
- De Azambuja, E (författare)
- University of Libre Brussels, Belgium
-
- Margeli Vila, M (författare)
- Hospital Badalona Germans Trias and Pujol, Spain
-
- Andersson, M (författare)
- Danish Breast Cancer Cooperat Grp, Denmark
-
- Nordenskjöld, Bo (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
-
- Jakesz, R (författare)
- Vienna Medical Sch, Austria
-
- Thuerlimann, B (författare)
- Kantonsspital, Switzerland
-
- Gutierrez, J (författare)
- Clin Las Condes, Chile
-
- Harvey, V (författare)
- Auckland City Hospital, New Zealand
-
- Punzalan, L (författare)
- University of Libre Brussels, Belgium
-
- DellOrto, P (författare)
- University of Milan, Italy
-
- Larsimont, D (författare)
- University of Libre Brussels, Belgium
-
- Steinberg, I (författare)
- Sanofi Oncol, England
-
- Gelber, R D. (författare)
- IBCSG, MA USA
-
- Piccart-Gebhart, M (författare)
- University of Libre Brussels, Belgium
-
- Viale, G (författare)
- University of Milan, Italy
-
- Di Leo, A (författare)
- Hospital Prato, Italy
-
visa färre...
-
(creator_code:org_t)
- Oxford University Press (OUP): Policy A1, 2013
- 2013
- Engelska.
-
Ingår i: Annals of Oncology. - : Oxford University Press (OUP): Policy A1. - 0923-7534 .- 1569-8041. ; 24:5, s. 1203-1211
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes. less thanbrgreater than less thanbrgreater thanMethods: Patients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m(2)) x 4 -andgt; classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600 mg/m(2)) x 4 -andgt; CMF; (iii) sequential docetaxel: A (75 mg/m(2)) x3 -andgt; docetaxel (T) (100 mg/m(2)) x3. CMF and (iv) concurrent docetaxel: AT(50/75 mg/m(2)) x 4 -andgt; CMF. The primary comparison evaluated docetaxel efficacy regardless of the schedule. Exploratory analyses were undertaken within biologically defined subtypes. less thanbrgreater than less thanbrgreater thanResults: Two thousand eight hundred and eighty-seven patients were enrolled. After 93.4 months of median follow-up, there were 916 DFS events. For the primary comparison, there was no significant improvement in DFS from docetaxel [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.80-1.05, P = 0.187]. In secondary comparisons, sequential docetaxel significantly improved DFS compared with sequential control (HR = 0.81, 95% CI = 0.67-0.99, P = 0.036), and significantly improved DFS (HR = 0.84, 95% CI = 0.72-0.99, P = 0.035) and overall survival (OS) (HR = 0.79, 95% CI = 0.65-0.98, P = 0.028) compared with concurrent doxorubicin-docetaxel. Luminal-A disease had the best prognosis. HRs favored addition of sequential docetaxel in all subtypes, except luminal-A; but this observation was not statistically supported because of limited numbers. less thanbrgreater than less thanbrgreater thanConclusion: With further follow-up, the sequential docetaxel schedule resulted in significantly better OS than concurrent doxorubicin-docetaxel, and continued to show better DFS than sequential doxorubicin-based control.
Nyckelord
- adjuvant
- breast cancer
- chemotherapy
- docetaxel
- doxorubicin
- sequential
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Oakman, C
-
Francis, P A.
-
Crown, J
-
Quinaux, E
-
Buyse, M
-
De Azambuja, E
-
visa fler...
-
Margeli Vila, M
-
Andersson, M
-
Nordenskjöld, Bo
-
Jakesz, R
-
Thuerlimann, B
-
Gutierrez, J
-
Harvey, V
-
Punzalan, L
-
DellOrto, P
-
Larsimont, D
-
Steinberg, I
-
Gelber, R D.
-
Piccart-Gebhart, ...
-
Viale, G
-
Di Leo, A
-
visa färre...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Linköpings universitet